PF-04995274 (PF04995274) is a novel and potent serotonin 4 receptor (5-HT4) partial agonist, acting centrally as a pro-cognitive agent with the potential to be used for the treatment of Alzheimer’s disease (AD).

Zotepine is a potent and 2nd generation antipsychotic with antidepressive and anxiolytic effects and can be used for the treatment for schizophrenia.

BRL 54443 (BRL54443; BRL-54443) is a potent agonist of 5-HT1E and 5-HT1F receptor with important biological activity.

Ondansetron (GRC-50775; GR-38032; SN-307; GR38032; SN307; GR-C507/75; Zofran), an approved antiemetic drug, is a potent serotonin 5-HT3 receptor antagonist which is used to prevent nausea and vomiting caused by cancer chemotherapy, and radiation therapy.

Lu AE58054 (also known as Idalopirdine) is potent and selective antagonist of the 5-HT(6) receptor with Ki value of 0.83 nM.

SB271046 (SB 271046; SB-271046; SB-271046A; SB271046A) is a novel, potent, selective and orally bioactive 5-HT6 receptor antagonist with important biological activity.

LY-344864 (LY344864) is a novel, potent and selective receptor agonist of 5-HT1F with Ki of 6 nM.

Loxapine Succinate (Loxapac; Adasuve; Cloxazepin; Daxolin; Oxilapine), the succinate salt of Loxapine which is a dibenzoxazepine anti-psychotic drug, is a potent D2DR/D4DR inhibitor as well as serotonergic receptor antagonist.

LP-211 is a potent and selective 5-HT7 receptor agonist with a Ki of 0.58 nM at rat cloned 5-HT7 receptors.

BMY 7378 (BMY-7378; BMY7378) is a multi-target compound that inhibits α2C-adrenoceptor and α1D-adrenoceptor with pKi values of 6.54 and 8.2, respectively.